LAG3 and melanoma: This phase II trial explored whether dual ICI, targeting both LAG-3 (lymphocyte-activation gene 3) and PD-1, could provide improved clinical benefit over PD-1 inhibition alone in patients with resectable clinical stage III or oligometastatic stage IV melanoma.